CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.36B, above the global median of $1.18B
- FinancialsAltman Z-Score 1.91: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.36BUSDvs all stocks (USD)
Trailing P/E
24.80xvs Medical Devices peers
Revenue (TTM)
1.37BUSDvs all stocks (USD)
Profit Margin
4.12%vs Medical Devices peers
Beta
0.9070xvs all stocks
52-Week Change
-0.63%vs all stocks
Market Capitalization
1.36BUSDvs all stocks (USD)
Enterprise Value
2.16BUSDvs all stocks (USD)
Trailing P/E
24.80xvs Medical Devices peers
Forward P/E
9.49xvs Medical Devices peers
PEG Ratio
2.14xvs Medical Devices peers
Price to Sales (TTM)
0.9909xvs Medical Devices peers
Price to Book (MRQ)
1.31xvs Medical Devices peers
Enterprise to Revenue
1.57xvs Medical Devices peers
Enterprise to EBITDA
9.48xvs Medical Devices peers
Gross Margin
57.49%vs Medical Devices peers
Profit Margin
4.12%vs Medical Devices peers
Operating Margin
14.64%vs Medical Devices peers
Return on Assets (TTM)
4.14%vs Medical Devices peers
Return on Equity (TTM)
5.53%vs Medical Devices peers
Revenue (TTM)
1.37BUSDvs all stocks (USD)
Revenue per Share (TTM)
44.70USDUpdated Sep 27, 2026Quarterly Revenue Growth
0.30%vs Medical Devices peers
Gross Profit (TTM)
762.31MUSDvs all stocks (USD)
EBITDA (TTM)
188.49MUSDvs all stocks (USD)
Net Income (TTM)
56.50MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.70%vs Medical Devices peers
Operating Cash Flow (TTM)
150.59MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
131.36MUSDvs all stocks (USD)
5-Year Average Dividend Yield
1.02%vs all stocks
Payout Ratio
10.81%vs Medical Devices peers
Revenue
1.37BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
624.25MUSDFY2025 · Dec 31, 2025Gross Profit
750.48MUSDFY2025 · Dec 31, 2025Operating Income
102.62MUSDvs all stocks (USD)
Pre-tax Income
71.12MUSDFY2025 · Dec 31, 2025Income Tax Expense
24.06MUSDFY2025 · Dec 31, 2025Net Income
47.05MUSDFY2025 · Dec 31, 2025EBIT
102.20MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
176.49MUSDFY2025 · Dec 31, 2025Research & Development
55.88MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
591.97MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
31.09MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.52USDFY2025 · Dec 31, 2025EPS (Diluted)
1.51USDFY2025 · Dec 31, 2025Basic Shares Outstanding
31.04MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
31.04MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
47.05MUSDFY2025 · Dec 31, 2025Operating Cash Flow
155.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
135.61MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
40.82MUSDFY2025 · Dec 31, 2025Interest Paid
25.42MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
47.05MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
74.28MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.52MUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.32MUSDFY2025 · Dec 31, 2025Other Non-cash Items
28.60MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.36MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-9.75MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-19.81MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.15MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-20.96MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
720.67MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-795.25MUSDFY2025 · Dec 31, 2025Common Dividends Paid
-24.75MUSDFY2025 · Dec 31, 2025Other Financing Charges
-36.49MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-135.82MUSDFY2025 · Dec 31, 2025Shares Outstanding
30.14MSharesUpdated Sep 27, 2026Float Shares
29.66MSharesUpdated Sep 27, 2026Shares Short
2.14MSharesUpdated Sep 27, 2026Short Ratio
7.02daysvs all stocks
Short % of Shares Outstanding
8.48%vs all stocks
% Held by Insiders
0.43%vs all stocks
% Held by Institutions
116.60%vs all stocks
Total Cash (MRQ)
37.33MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.25USDUpdated Sep 27, 2026Total Debt (MRQ)
834.25MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.8011xvs Medical Devices peers
Current Ratio (MRQ)
1.48xvs Medical Devices peers
Book Value per Share (MRQ)
34.73USDUpdated Sep 27, 2026Total Assets
2.33BUSDvs all stocks (USD)
Total Current Assets
672.86MUSDFY2025 · Dec 31, 2025Total Liabilities
1.29BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.65BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
977.61MUSDFY2025 · Dec 31, 2025Total Current Liabilities
315.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.82MUSDFY2025 · Dec 31, 2025Accounts Receivable
247.83MUSDFY2025 · Dec 31, 2025Inventory
355.54MUSDFY2025 · Dec 31, 2025Accounts Payable
93.65MUSDFY2025 · Dec 31, 2025Short-term Debt
712.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
138.54MUSDFY2025 · Dec 31, 2025Long-term Debt
834.23MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
63.85MUSDFY2025 · Dec 31, 2025Common Stock (Book)
313.00KUSDFY2025 · Dec 31, 2025Retained Earnings
588.77MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.03BUSDvs all stocks (USD)
Treasury Stock
12.89MUSDFY2025 · Dec 31, 202552-Week Low
31.44USDUpdated Sep 27, 202652-Week High
53.66USDUpdated Sep 27, 202652-Week Change
-0.63%vs all stocks
Beta
0.9070xvs all stocks
50-Day MA
47.51USDUpdated Sep 27, 2026200-Day MA
40.72USDUpdated Sep 27, 2026Avg 10-Day Volume
399.87KSharesUpdated Sep 27, 2026Avg 30-Day Volume
328.09KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
1.83USDUpdated Sep 27, 2026Other Income / Expense
-418.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
How is this stock valued?
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
How does this company return capital?
Long Dividend Streak With Three-Year FCF Coverage
Years of uninterrupted dividends, covered by free cash flow on a three-year average.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.04
Financial Health
Altman Z-Score 1.91: grey zoneSignificant
Altman Z-Score: 1.91
High earnings qualityNotable
Earnings Quality Score: 1.15
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.36B, above the global median of $1.18BNotable
Market cap (USD): 1,359,187,634Global Median: 1,180,223,658.953
Revenue is $1.37B, above the global median of $548.88MNotable
Revenue (USD): 1,371,657,984Global Median: 548,883,780.48
Levered free cash flow is $131.36M, above the global median of $18.73MNotable
Levered free cash flow (USD): 131,359,624Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Brown & Brown Inc.
3 interpretationsMulti-Year FCF With Growth And MarginDrawdown With FCF And Cash BackingLong Dividend Streak With Three-Year FCF Coverage
Fiverr International Ltd.
2 interpretationsMulti-Year FCF With Growth And MarginDrawdown With FCF And Cash Backing
Globant S.A.
2 interpretationsMulti-Year FCF With Growth And MarginDrawdown With FCF And Cash Backing